{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:01:06Z","timestamp":1785211266270,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.trecan.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:30:03Z","timestamp":1785209403000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of mantle cell lymphoma therapy: advancing frontline precision"],"prefix":"10.1016","author":[{"given":"Shijia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.07.001_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.07.001_bb0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/leu.2009.31","article-title":"t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals","volume":"23","author":"Lecluse","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2026.07.001_bb0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2026.07.001_bb0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0055","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2352-3026(21)00237-4","article-title":"The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma","volume":"8","author":"Chiappella","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0060","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41409-025-02599-x","article-title":"How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives","volume":"60","author":"Dreger","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trecan.2026.07.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000464","article-title":"EHA endorsement of ESMO clinical practice guidelines for newly diagnosed and relapsed mantle cell lymphoma","volume":"4","author":"Linton","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.trecan.2026.07.001_bb0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2016.1.419","article-title":"Frontline therapy and role of high-dose consolidation in mantle cell lymphoma","volume":"2016","author":"Rule","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.trecan.2026.07.001_bb0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0080","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trecan.2026.07.001_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0090","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0095","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0105","article-title":"First-line autologous stem cell transplantation for mantle cell lymphoma: a systematic analysis and treatment recommendation","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0110","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-018-0800-9","article-title":"Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy","volume":"37","author":"Ye","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.001_bb0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0130","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO-25-00146","article-title":"Mantle cell lymphoma: optimal treatment with Bruton tyrosine kinase-targeted approaches","volume":"43","author":"Eyre","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0140","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0145","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2021-153390","article-title":"Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-HyperCVAD\/MTX in young patients with previously untreated mantle cell lymphoma \u2013 phase-II window-2 clinical trial","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0150","doi-asserted-by":"crossref","first-page":"911.e1","DOI":"10.1016\/j.jtct.2021.08.014","article-title":"Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma","volume":"27","author":"Riedell","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.trecan.2026.07.001_bb0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0160","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.07.001_bb0165","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0170","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/bloodadvances.2024015292","article-title":"BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma","volume":"9","author":"Gutmair","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.07.001_bb0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0180","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/cas.13719","article-title":"R-high-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY","volume":"109","author":"Ogura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.trecan.2026.07.001_bb0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2021.279037","article-title":"Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen \u2013 a real world study on patients diagnosed in Sweden 2007\u20132017","volume":"107","author":"Albertsson-Lindblad","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2026.07.001_bb0190","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.07.001_bb0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.07.001_bb0200","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0205","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0210","doi-asserted-by":"crossref","first-page":"e777","DOI":"10.1016\/S2352-3026(25)00252-2","article-title":"Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study","volume":"12","author":"Visco","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0215","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0220","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.trecan.2026.07.001_bb0230","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.07.001_bb0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2024-192939","article-title":"Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator \u2013 the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial","volume":"144","author":"Jerkeman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","article-title":"Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group","volume":"13","author":"Yoon","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0245","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0250","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1186\/s12885-025-14803-8","volume":"25","author":"Herold","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.07.001_bb0255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0260","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0265","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2025-884","article-title":"Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): results from the Phase 2 TrAVeRse study","volume":"146","author":"Hawkes","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0270","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0275","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","article-title":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma","volume":"108","author":"Liu","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2026.07.001_bb0280","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0285","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/bloodadvances.2025017760","article-title":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma","volume":"10","author":"Ruan","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.07.001_bb0290","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1182\/blood-2025-5386","article-title":"Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients","volume":"146","author":"Rivero","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0295","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0300","article-title":"Mantle cell lymphoma manifests in multiple morphologies within the colorectum","author":"Tang","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0305","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2026.07.001_bb0310","article-title":"Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma","volume":"6","author":"Wan","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0315","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2019-129404","article-title":"Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine + rituximab without autologous transplant","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.07.001_bb0320","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.07.001_bb0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-025-01241-9","article-title":"Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study","volume":"15","author":"Sarkozy","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2026.07.001_bb0330","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2026.07.001_bb0335","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/bloodadvances.2025018527","article-title":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma","volume":"10","author":"Wang","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.07.001_bb0340","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers17111889","article-title":"A triple oral combination of bendamustine, acalabrutinib, and venetoclax demonstrates efficacy against mantle cell lymphoma in vitro and in vivo","volume":"17","author":"Filioglou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.07.001_bb0345","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/bloodadvances.2023011920","article-title":"MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial","volume":"8","author":"Jerkeman","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.07.001_bb0350","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022 \u2013 a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trecan.2026.07.001_bb0355","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1182\/bloodadvances.2025017086","article-title":"Multifaceted cfDNA profiling in mantle cell lymphoma","volume":"9","author":"Sworder","year":"2025","journal-title":"Blood Adv."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:30:12Z","timestamp":1785209412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":71,"alternative-id":["S2405803326001573"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of mantle cell lymphoma therapy: advancing frontline precision","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}